Sexual Health Peptides: FDA-Approved & Research Compounds
The sexual health peptide category includes PT-141 (Bremelanotide), marketed as Vyleesi — one of the few FDA-approved peptide drugs outside the GLP-1 class. PT-141 activates melanocortin receptors to treat hypoactive sexual desire disorder in premenopausal women.
PT-141 is unique in the peptide space because it targets the central nervous system rather than peripheral vascular pathways, meaning it can work when PDE5 inhibitors like Viagra fail. Clinical trials supporting Vyleesi showed modest but statistically significant improvements in desire and reduction in distress among premenopausal women with HSDD. Off-label use in men for erectile dysfunction is common but less well-studied. Melanotan II, another peptide in this category, is associated with significant safety concerns — uncontrolled pigmentation, potential melanoma risk, and nausea severe enough to cause fainting — and is not approved anywhere for human use. The category overall has one well-validated FDA-approved option (PT-141 for women) and several research-only compounds with meaningful risk profiles.
2 compounds in this category
Key Takeaways
- PT-141 (Vyleesi) is FDA-approved for premenopausal women with HSDD
- PT-141 works via CNS melanocortin receptors, not vascular pathways like PDE5 inhibitors
- Off-label male use is common but less well-studied
- Melanotan II carries serious safety concerns and is not approved for human use
- Side effects for PT-141 include nausea, flushing, and transient blood pressure elevation
Compounds in This Category
PT-141Bremelanotide, Vyleesi
An FDA-approved melanocortin receptor agonist used for hypoactive sexual desire disorder in premenopausal women.
Melanotan IIMT-2, MT-II
A melanocortin receptor agonist that stimulates melanin production (tanning) and has sexual function effects. Significant safety concerns.
Frequently Asked Questions
Is PT-141 FDA-approved?
Yes, PT-141 (bremelanotide) is FDA-approved under the brand name Vyleesi for hypoactive sexual desire disorder in premenopausal women.
Does PT-141 work for men?
Off-label use is common, and clinical studies in male erectile dysfunction exist, but it is not FDA-approved for this indication. It may work when PDE5 inhibitors fail because it acts centrally.
What are the main PT-141 side effects?
Nausea (occurring in roughly 40% of users in trials), facial flushing, and transient blood pressure elevation are the most common effects.
Is Melanotan II safe?
No. Melanotan II has been associated with uncontrolled pigmentation, nausea severe enough to cause fainting, and potential melanoma risk. It is not approved anywhere for human use.
How long does PT-141 take to work?
Effects typically emerge within 30–60 minutes of subcutaneous injection and last several hours.